全文获取类型
收费全文 | 57443篇 |
免费 | 6665篇 |
国内免费 | 1145篇 |
专业分类
耳鼻咽喉 | 281篇 |
儿科学 | 1540篇 |
妇产科学 | 1123篇 |
基础医学 | 3832篇 |
口腔科学 | 1350篇 |
临床医学 | 7457篇 |
内科学 | 10831篇 |
皮肤病学 | 530篇 |
神经病学 | 3825篇 |
特种医学 | 1914篇 |
外国民族医学 | 1篇 |
外科学 | 5216篇 |
综合类 | 6805篇 |
现状与发展 | 8篇 |
一般理论 | 10篇 |
预防医学 | 9705篇 |
眼科学 | 965篇 |
药学 | 5073篇 |
39篇 | |
中国医学 | 778篇 |
肿瘤学 | 3970篇 |
出版年
2024年 | 60篇 |
2023年 | 1269篇 |
2022年 | 1568篇 |
2021年 | 2917篇 |
2020年 | 3047篇 |
2019年 | 2729篇 |
2018年 | 2722篇 |
2017年 | 2673篇 |
2016年 | 2720篇 |
2015年 | 2523篇 |
2014年 | 4555篇 |
2013年 | 5289篇 |
2012年 | 3722篇 |
2011年 | 3864篇 |
2010年 | 2952篇 |
2009年 | 2745篇 |
2008年 | 2766篇 |
2007年 | 2533篇 |
2006年 | 2255篇 |
2005年 | 1909篇 |
2004年 | 1582篇 |
2003年 | 1301篇 |
2002年 | 1126篇 |
2001年 | 978篇 |
2000年 | 776篇 |
1999年 | 647篇 |
1998年 | 545篇 |
1997年 | 458篇 |
1996年 | 375篇 |
1995年 | 368篇 |
1994年 | 295篇 |
1993年 | 282篇 |
1992年 | 235篇 |
1991年 | 191篇 |
1990年 | 144篇 |
1989年 | 149篇 |
1988年 | 133篇 |
1987年 | 110篇 |
1986年 | 85篇 |
1985年 | 124篇 |
1984年 | 108篇 |
1983年 | 57篇 |
1982年 | 79篇 |
1981年 | 64篇 |
1980年 | 56篇 |
1979年 | 39篇 |
1978年 | 26篇 |
1977年 | 27篇 |
1976年 | 26篇 |
1975年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
73.
74.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献75.
《Vaccine》2019,37(35):4906-4919
IntroductionIn 2016, more than 600,000 persons were being held in EU/EEA correctional facilities on a given day. People in prison may be at risk of vaccine-preventable diseases. While vaccination recommendations for people in prison exist, little is known on coverage and implementation options.MethodsWe performed a systematic review on existing evidence on vaccination in prison settings in the EU/EEA. We searched peer-reviewed and grey literature following international methodology and reporting standards, to gather records published between 1980 and 2016 in all languages. We analysed quantitative (acceptance, uptake, cost-effectiveness) and qualitative (barriers) outcomes.ResultsOut of 7041 identified records, 19 full-text articles were included from peer-reviewed literature and two from grey literature. Of these, 18 reported on hepatitis A and/or B virus (HAV/HBV), two on influenza and one on MMR vaccination. Two studies on HAV vaccine reported varying acceptance (5–91%) and uptake rates (62.9–70.5%). Seven studies reported on HBV vaccination. A comparative study showed a significantly higher uptake of the third HBV vaccine dose with the very rapid (63%) compared to the standard schedule (20%). HBV vaccination was generally well accepted (54–100%), whereas uptake was variable (dose 1:23–100%, dose 2:48–92%, dose 3:19–80%). One study on the combined HAV/HBV vaccine reported an acceptance rate of 34%, and declining uptake following dose 1. One study on influenza vaccine showed an uptake of 42–46%, while another reported a MMR vaccine acceptance of 80% and an uptake of 74%. Overall, main reasons for non-vaccination included release from/or transfer between prisons, and refusal.ConclusionsThis systematic review highlighted important knowledge gaps and operational challenges for vaccination in prison settings. Vaccination is an effective measure that warrants comprehensive and tailored implementation to reduce the preventable disease burden, avoid risks of large outbreaks of vaccine-preventable diseases, and contribute to health equity for people in prison. 相似文献
76.
《Vaccine》2019,37(47):7003-7010
Control and prevention of rapid influenza spread among humans depend on the availability of efficient and safe seasonal and pandemic vaccines, made primarily from inactivated influenza virus particles. Current influenza virus production processes rely heavily on embryonated chicken eggs or on cell culture as substrate for virus propagation. Today’s efforts towards process intensification in animal cell culture could innovate viral vaccine manufacturing using high-yield suspension cells in high cell density perfusion processes. In this work, we present a MDCK cell line adapted to grow as single cell suspension with a doubling time of less than 20 h, achieving cell concentrations over 1 × 107 cells/mL in batch mode. Influenza A virus titer obtained in batch infections were 3.6 log10(HAU/100 µL) for total- and 109 virions/mL for infectious virus particles (TCID50), respectively. In semi-perfusion mode concentrations up to 6 × 107 cells/mL, accumulated virus titer of 4.5 log10(HAU/100 µL) and infectious titer of almost 1010 virions/mL (TCID50) were possible. This exceeds results reported previously for cell culture-based influenza virus propagation by far and suggests perfusion cultures as the preferred method in viral vaccine manufacturing. 相似文献
77.
Sandrine F. Chebekoue 《Journal of occupational and environmental hygiene》2019,16(4):308-319
This study aimed at deriving occupational thresholds of toxicological concern for inhalation exposure to systemically-acting organic chemicals using predicted internal doses. The latter were also used to evaluate the quantitative relationship between occupational exposure limit and internal dose. Three internal dose measures were identified for investigation: (i) the daily area under the venous blood concentration vs. time curve, (ii) the daily rate of the amount of parent chemical metabolized, and (iii) the maximum venous blood concentration at the end of an 8-hr work shift. A dataset of 276 organic chemicals with 8-hr threshold limit values-time-weighted average was compiled along with their molecular structure and Cramer classes (Class I: low toxicity, Class II: intermediate toxicity, Class III: suggestive of significant toxicity). Using a human physiologically-based pharmacokinetic model, the three identified dose metrics were predicted for an 8-hr occupational inhalation exposure to the threshold limit value for each chemical. Distributional analyses of the predicted dose metrics were performed to identify the percentile values corresponding to the occupational thresholds of toxicological concern. Also, simple linear regression analyses were performed to evaluate the relationship between the 8-hr threshold limit value and each of the predicted dose metrics, respectively. No threshold of toxicological concern could be derived for class II due to few chemicals. Based on the daily rate of the amount of parent chemical metabolized, the proposed internal dose-based occupational thresholds of toxicological concern were 5.61?×?10?2 and 9?×?10?4 mmol/d at the 10th percentile level for classes I and III, respectively, while they were 4.55?×?10?1 and 8.5?×?10?3 mmol/d at the 25th percentile level. Even though high and significant correlations were observed between the 8-hr threshold limit values and the predicted dose metrics, the one with the rate of the amount of chemical metabolized was remarkable regardless of the Cramer class (r2 = 0.81; n = 276). The proposed internal dose-based occupational thresholds of toxicological concern are potentially useful for screening-level assessments as well as prioritization within an integrated occupational risk assessment framework. 相似文献
78.
《The Journal for Nurse Practitioners》2019,15(1):139-145.e1
This study explored the lived experiences of family members who were referred to a cardiogenetics clinic after the loss of a family member to sudden cardiac death. Participants revealed many health concerns and emotions, including disappointment, guilt, ambivalence, blame, and fear of loss. Understanding these findings and their potential effect on the family members may provide nurse practitioners with the ability to improve the quality of care that is offered to family members after sudden cardiac death and further the knowledge for genetic testing and disease management. 相似文献
79.
目的探讨GATA6基因启动区-493(rs144923558)G/A、-172(rs146748749)G/A 2个位点单核苷酸多态性(SNP)与急性心肌梗死(AMI)之间的关系及其相关的危险因素。方法采用病例-对照研究方法,收集328例AMI患者和344例正常对照;应用聚合酶链反应-限制性内切酶片段长度多态性技术结合DNA测序后的序列比对进行数据统计;运用Hardy-Weinberg平衡检验后,应用χ~2检验进行相关分析;利用Logistic回归对多种危险因素以及2个SNP位点与AMI发病进行关联性分析;利用Haplovview4.2软件和SHEsis网站进行连锁不平衡及单倍体分析。结果 2个SNP位点共检测出3种基因型为GG、GA和AA,其基因型分布均符合Hardy-Weinberg平衡(P0.05),同时在AMI组与对照组间差异无显著性(P0.05)。多因素Logistic回归分析:增龄、高血压病、吸烟、低密度脂蛋白胆固醇(LDLC)和甘油三酯(TG)升高是AMI发病的独立危险因素(P0.05),HDLC为保护因素(P0.05)。在显性、隐性和加性3种不同遗传模式下进行Logistic回归分析发现,2个SNP位点与AMI发病无关联性。进行连锁不平衡和单倍型分析提示,该2个SNP位点处于同一个连锁不平衡区域(D′=1.000,r~2=1.000),单倍型GG和AA均未增加AMI易感性(P0.05)。结论 GATA6基因启动区-493(rs144923558)G/A与-172(rs146748749)G/A两个SNP位点为完全连锁不平衡,其中GG为主要单倍型。该2个SNP位点及其单倍体型与AMI发病无相关性,但提供了GATA6基因启动区多态性的群体遗传学资料。 相似文献
80.